Source-grounded facts extracted from Xeris Biopharma Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Xeris Biopharma Holdings, Inc. reported the three months ended March 31, 2026 results: revenue $83,127, net income $2.2 million.
“Three months ended March 31, Change 2026 2025 $ % Product revenue (in thousands): Recorlev $ 49,768 $ 25,530 $ 24,238 95 Gvoke 20,800 20,845 (45) — Keveyis 11,886 11,427 459 4 Product revenue, net 82,454 57,802 24,652 43 Royalty, contract and other revenue 673 2,317 (1,644) (71) Total revenue $ 83,127 $ 60,119 $ 23,008 38”
James Brady was appointed as Director at Xeris Biopharma Holdings, Inc..
“On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.”
John Schmid departed as Director at Xeris Biopharma Holdings, Inc..
“On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).”
Ricki Fairley resigned as Director at Xeris Biopharma Holdings, Inc..
“On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.”
Ken Johnson retired as Senior Vice President, Global Development and Medical Affairs at Xeris Biopharma Holdings, Inc..
“On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the “Company”) of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.”
Kevin McCulloch changed role as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..
“The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.”
Marla S. Persky was appointed as Chairperson of the Board at Xeris Biopharma Holdings, Inc..
“Marla S. Persky, currently a Class III director of the Company, has been appointed by the Board to serve as the Chairperson of the Board, effective as of the Transition Date.”
John Shannon was appointed as Class III Director at Xeris Biopharma Holdings, Inc..
“The Board also approved the appointment of Mr. Shannon as a Class III director, effective as of the Transition Date.”
John Shannon was appointed as Chief Executive Officer at Xeris Biopharma Holdings, Inc..
“John Shannon, currently the Company’s President and Chief Operating Officer, has been appointed by the Board to serve as the Company’s Chief Executive Officer, effective as of the Transition Date.”
Paul R. Edick resigned as Chairman of the Board at Xeris Biopharma Holdings, Inc..
“On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.”
Paul R. Edick resigned as Chief Executive Officer at Xeris Biopharma Holdings, Inc..
“On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.”
Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $40,638, net income $19.0 million, or $0.14 per share. Guidance reaffirmed.
“13,085 12,755 330 2.6 Recorlev 10,599 4,477 6,122 136.7 Product revenue, net 40,263 32,265 7,998 24.8 Royalty, contract and other revenue 375 931 (556) (59.7) Total revenue $ 40,638 $ 33,196 $ 7,442 22.4 Commercial Products • Gvoke® : First quarter net revenue was $16.6 million as compared to $15.0 million in the first quarter of 2023 – an increase of”
Xeris Biopharma Holdings, Inc. reported financial results for the three and twelve months ended December 31, 2023.
“On March 6, 2024, the Company issued a press release containing information about the Company's results of operations and business highlights for the three and twelve months ended December 31, 2023.”
Xeris Biopharma Holdings, Inc. incurred term loan of $15.2 million in additional term loans (the “Tranche 2 Loans”) with Hayfin Services LLP maturing March 5, 2029.
“$15.2 million in additional term loans (the “Tranche 2 Loans” and, together with the Tranche 1 Loans, the “2029 Loans”) on any date after the closing date and through July 15, 2025”
Xeris Biopharma Holdings, Inc. incurred term loan of $200.0 million in term loans (the “Tranche 1 Loans”) with Hayfin Services LLP at (i) 6.95% (or 5.95% if the replacement rate is in effect) plus (ii) the greater maturing March 5, 2029.
“The Amended and Restated Credit Agreement provided for the New Lenders to extend $200.0 million in term loans (the “Tranche 1 Loans”) to Xeris Pharma on the closing date”
Xeris Biopharma Holdings, Inc. entered into Amended and Restated Credit Agreement with Hayfin Services LLP, as administrative agent valued at $200.0 million in term loans (effective 2024-03-05).
“On March 5, 2024, Xeris Biopharma Holdings, Inc. (the “Company”), Xeris Pharmaceuticals, Inc. (“Xeris Pharma”) and certain subsidiary guarantors of the Company entered into an Amended and Restated Credit Agreement and Guaranty (the “Amended and Restated Credit Agreement”) with the lenders from time to time parties thereto (the “New Lenders”) and Hayfin Services LLP, as administrative agent for the New Lenders”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.